Kemp T - Search Results

1

Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.

Watson-Jones D, Changalucha J, Whitworth H, Pinto L, Mutani P, Indangasi J, Kemp T, Hashim R, Kamala B, Wiggins R, Songoro T, Connor N, Mbwanji G, Pavon MA, Lowe B, Mmbando D, Kapiga S, Mayaud P, de SanJosé S, Dillner J, Hayes RJ, Lacey CJ, Baisley K. Watson-Jones D, et al. Among authors: kemp t. Lancet Glob Health. 2022 Oct;10(10):e1473-e1484. doi: 10.1016/S2214-109X(22)00309-6. Lancet Glob Health. 2022. PMID: 36113531 Free PMC article. Clinical Trial.

2

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.

Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A. Pinto LA, et al. Among authors: kemp tj. Virology. 2006 Sep 30;353(2):451-62. doi: 10.1016/j.virol.2006.06.021. Epub 2006 Jul 24. Virology. 2006. PMID: 16863657 Free article. Clinical Trial.

3

Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.

García-Piñeres A, Hildesheim A, Dodd L, Kemp TJ, Williams M, Harro C, Lowy DR, Schiller JT, Pinto LA. García-Piñeres A, et al. Among authors: kemp tj. Clin Vaccine Immunol. 2007 Aug;14(8):984-9. doi: 10.1128/CVI.00090-07. Epub 2007 Jun 27. Clin Vaccine Immunol. 2007. PMID: 17596432 Free PMC article. Clinical Trial.

4

Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.

Kemp TJ, Hildesheim A, Falk RT, Schiller JT, Lowy DR, Rodriguez AC, Pinto LA. Kemp TJ, et al. Clin Vaccine Immunol. 2008 Jan;15(1):60-4. doi: 10.1128/CVI.00118-07. Epub 2007 Nov 21. Clin Vaccine Immunol. 2008. PMID: 18032596 Free PMC article. Clinical Trial.

5

Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.

García-Piñeres AJ, Hildesheim A, Dodd L, Kemp TJ, Yang J, Fullmer B, Harro C, Lowy DR, Lempicki RA, Pinto LA. García-Piñeres AJ, et al. J Immunol. 2009 Feb 1;182(3):1706-29. doi: 10.4049/jimmunol.182.3.1706. J Immunol. 2009. PMID: 19155521 Free PMC article. Clinical Trial.

6

Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection.

Kemp TJ, Hildesheim A, García-Piñeres A, Williams MC, Shearer GM, Rodriguez AC, Schiffman M, Burk R, Freer E, Bonilla J, Herrero R, Pinto LA. Kemp TJ, et al. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1954-9. doi: 10.1158/1055-9965.EPI-10-0184. Epub 2010 Jul 20. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20647411 Free PMC article.

7

Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection.

Baker R, Dauner JG, Rodriguez AC, Williams MC, Kemp TJ, Hildesheim A, Pinto LA. Baker R, et al. Cytokine. 2011 Mar;53(3):282-5. doi: 10.1016/j.cyto.2010.11.014. Epub 2010 Dec 16. Cytokine. 2011. PMID: 21167737 Free PMC article.

8

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.

Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA. Kemp TJ, et al. Vaccine. 2011 Mar 3;29(11):2011-4. doi: 10.1016/j.vaccine.2011.01.001. Epub 2011 Jan 15. Vaccine. 2011. PMID: 21241731 Free PMC article.

9

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.

Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; CVT Vaccine Group. Kreimer AR, et al. J Natl Cancer Inst. 2011 Oct 5;103(19):1444-51. doi: 10.1093/jnci/djr319. Epub 2011 Sep 9. J Natl Cancer Inst. 2011. PMID: 21908768 Free PMC article. Clinical Trial.

10

Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Dauner JG, Pan Y, Hildesheim A, Kemp TJ, Porras C, Pinto LA. Dauner JG, et al. Mol Cell Probes. 2012 Apr;26(2):73-80. doi: 10.1016/j.mcp.2012.01.002. Epub 2012 Jan 18. Mol Cell Probes. 2012. PMID: 22285687 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

320 results

Search Page